GLSI-100 (GP2 + GM-CSF)
Prevention of recurrence in HLA-A*02 positive, HER2/neu positive breast cancer (adjuvant setting)
Key Facts
About Greenwich LifeSciences
Greenwich LifeSciences is focused on developing breakthrough immunotherapies to prevent breast cancer recurrence, targeting a critical unmet need for millions of survivors. Its lead candidate, GLSI-100 (GP2 + GM-CSF), demonstrated an 80% or greater reduction in recurrence rates in a Phase IIb trial led by MD Anderson. The company is now advancing this candidate through a large, global Phase III trial with a distinguished steering committee and has strong manufacturing readiness with commercial-scale product already produced. Management and board ownership exceeds 50%, aligning strongly with shareholder interests.
View full company profileAbout Greenwich LifeSciences
Greenwich LifeSciences is focused on developing breakthrough immunotherapies to prevent breast cancer recurrence, targeting a critical unmet need for millions of survivors. Its lead candidate, GLSI-100 (GP2 + GM-CSF), demonstrated an 80% or greater reduction in recurrence rates in a Phase IIb trial led by MD Anderson. The company is now advancing this candidate through a large, global Phase III trial with a distinguished steering committee and has strong manufacturing readiness with commercial-scale product already produced. Management and board ownership exceeds 50%, aligning strongly with shareholder interests.
View full company profile